Table 2. Risks of Overall and Specific Cancers in Male and Female Patients With Hidradenitis Suppurativa (HS) Compared With a Matched Control Cohort.

Cancer subtype	Male with vs without HS		Female with vs without HS
	Adjusted HR (95% CI)a	P value	Adjusted HR (95% CI)a	P value
Overall	1.37 (1.19-1.57)	<.001	1.15 (0.96-1.37)	.13
Oral cavity and pharyngeal	2.80 (1.25-6.25)	.01	3.95 (1.21-12.89)	.02
Esophageal	1.61 (0.47-5.53)	.45	NE
Gastric	0.93 (0.64-1.35)	.69	1.30 (0.74-2.29)	.36
Small intestine	2.72 (0.55-13.57)	.22	NE
Colorectal	1.30 (0.91-1.87)	.16	1.79 (1.12-2.88)	.02
Liver	1.15 (0.72-1.83)	.57	0.90 (0.32-2.54)	.85
Biliary	1.88 (0.82-4.30)	.14	0.63 (0.15-2.63)	.52
Pancreatic	1.75 (0.82-3.76)	.15	0.31 (0.04-2.28)	.25
Laryngeal	0.59 (0.08-4.49)	.61	NE
Lung	1.39 (0.95-2.03)	.09	0.84 (0.36-1.95)	.68
Bone and articular cartilage	NE		10.33 (0.63-169.43)	.10
Malignant melanoma skin	2.06 (0.23-18.78)	.52	NE
Nonmelanoma skin	2.73 (1.33-5.61)	.006	1.12 (0.33-3.74)	.86
Breast	NE		1.22 (0.81-1.82)	.34
Uterine cervical	NE		0.38 (0.09-1.58)	.18
Uterine corpus	NE		0.85 (0.20-3.66)	.83
Ovarian	NE		1.07 (0.32-3.55)	.91
Prostate	2.05 (1.30-3.24)	.002	NE
Testicular	1.03 (0.13-8.20)	.98	NE
Renal	1.26 (0.57-2.80)	.57	1.93 (0.54-6.86)	.31
Bladder	0.65 (0.23-1.80)	.41	NE
Central nervous system	3.14 (1.38-7.15)	.006	1.49 (0.44-5.05)	.53
Thyroid	1.52 (0.95-2.42)	.08	1.04 (0.73-1.49)	.82
Adrenal	NE		4.70 (0.28-77.83)	.28
Lymphoma	2.39 (1.13-5.03)	.02	0.71 (0.17-3.01)	.64
Hodgkin lymphoma	8.68 (1.74-43.28)	.008	NE
Non-Hodgkin lymphoma	1.75 (0.72-4.23)	.22	0.78 (0.18-3.34)	.73
Multiple myeloma	1.13 (0.14-9.27)	.91	2.94 (0.30-28.59)	.35
Leukemia	1.74 (0.66-4.56)	.26	1.13 (0.26-4.96)	.87

Abbreviations: HR, hazard ratio; NE, not estimated.

^aAdjusted for the presence of hypertension and dyslipidemia.